<DOC>
	<DOCNO>NCT01285934</DOCNO>
	<brief_summary>Type 1 diabetes mellitus ( T1D ) result immune-mediated destruction insulin-producing islet cell . The loss islet cell traditionally treat insulin therapy case pancreas islet cell transplantation . Another approach would preserve islet cell mass irreversibly lose . Previous trial use immune suppression within 6 week T1D onset demonstrate diminished exogenous insulin requirement compare untreated control . In prior phase I non-randomized study , extend immune suppression point immune ablation / immune reset autologous HSC support , several patient new onset T1D maintain insulin-free , drug free remission 4 year . Although result appear highly promising , may argue result mitigate documented honeymoon effect follow T1D , normal transient insulin free interval occur disease onset patient . The goal trial extend phase I study new onset T1D clarify whether post transplant insulin free interval due treatment intervention ( transplant ) result normally occur `` insulin free honeymoon period '' . Both group receive identical change life style ( i.e . diet , exercise ) education .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Support Versus Insulin T1D</brief_title>
	<detailed_description>Eligible patient type 1 diabetes ( age ≥ 18 year old ) within five month disease diagnosis , positive antibody islet cell autoantigen , fast C-peptide &gt; 0.2 nmol/l . Hematopoietic stem cell mobilize cyclophosphamide ( 2.0 g/m2 ) granulocyte colony-stimulating factor ( 10 g/kg/day ) collect peripheral blood leukoapheresis cryopreserved . HSC inject IV condition cyclophosphamide ( 200 mg/kg ) divide 50 mg/kg day -5 , -4 , -3 , -2 , rabbit antithymocyte globulin ( 4.5 mg/kg ) divide 0.5 mg/kg day-5 , 1.0 mg/kg day -4 , -3- , -2 , -1 . Rituxan ( 500mg ) IV give day -6 +1 . The control arm receive either continuous subcutaneous insulin infusion ( CSII ) intensive subcutaneous insulin therapy multiple insulin injection ( least 4/day ) utilizing long act background insulin pre-meal rapid act insulin . The main outcome measure : fasting C-peptide . Other outcome measure include : daily exogenous insulin requirement , serum level hemoglobin A1c , area curve ( AUC ) C-peptide level mixed meal tolerance test , islet cell autoantigen antibody titer , quality life ( QOL ) short form 36 ( SF-36 ) questionnaire .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Ages 16 35 year old A diagnosis type 1 diabetes hyperglycemia least 1 antibody islet cell autoantigen : GAD , IAA , ICA , IA2 , Slc30A8 Fasting Cpeptide &gt; 0.20 nmol / liter Enrollment within 5 month T1D diagnosis Eligible patient must refer fertility / reproductive endocrinologist write documentation medical counseling advise patient risk infertility possible option sperm oocyte banking enrollment . HIV positive Patients honeymoon phase take insulin Hepatitis A , B , C positive On corticosteroid immune suppressive medication History diabetic ketoacidosis Ongoing malignancy except localize treated basal cell squamous skin cancer . History cardiac disease congestive heart failure ventricular tachycardia abnormal dobutamine cardiac echocardiogram Positive pregnancy test , inability unwillingness pursue effective mean birth control , failure willingly accept comprehend irreversible sterility potential side effect therapy . Psychiatric illness mental deficiency make compliance treatment inform consent impossible . DLCO &lt; 60 % predict Resting LVEF &lt; 45 % Creatinine &gt; 1.5 mg/dl Known hypersensitivity E Coli derive protein . Transaminases great 2 time normal Positive tuberculosis skin test Any active infection Any comorbid illness opinion investigator would jeopardize ability subject tolerate study . Failure collect least 2.0 x 106 CD34+ cells/kg History alcohol illicit drug abuse Unwilling compliant change lifestyle—diet exercise</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>